TABLE 1.
Characteristics of the Study Sample (n=761)
| All survivors* N= 761 |
Active disease†n=109 |
Short-term survivor╪n=150 |
Long-term survivor§ n=502 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Demographics (DEM) | N | % | N | % | N | % | N | % | P-value | |
| Gender | ||||||||||
| Male | 383 | 50.3 | 54 | 49.5 | 73 | 48.7 | 256 | 51.0 | .868 | |
| Female | 378 | 49.7 | 55 | 50.5 | 77 | 51.3 | 246 | 49.0 | ||
| Race | ||||||||||
| Caucasian | 659 | 86.6 | 88 | 80.7 | 133 | 88.7 | 438 | 87.3 | .103 | |
| African-American | 67 | 8.8 | 15 | 13.8 | 10 | 6.7 | 42 | 8.4 | ||
| Multiple race | 27 | 3.5 | 5 | 4.6 | 5 | 3.3 | 17 | 3.4 | ||
| Other | 8 | 1.1 | 1 | 0.9 | 2 | 1.3 | 5 | 0.9 | ||
| Ethnicity | ||||||||||
| Non-Hispanic | 750 | 98.6 | 107 | 98.2 | 148 | 98.7 | 495 | 98.6 | .933 | |
| Hispanic | 11 | 1.4 | 2 | 1.8 | 2 | 1.3 | 7 | 1.4 | ||
| Income level | ||||||||||
| < $30,000 | 183 | 26.7 | 28 | 28.0 | 32 | 21.3 | 123 | 27.3 | .763 | |
| $30,000 – $59,999 | 208 | 30.3 | 32 | 32.0 | 39 | 26.0 | 137 | 30.4 | ||
| $60,000 – $89,999 | 126 | 18.4 | 21 | 21.0 | 27 | 18.0 | 78 | 17.3 | ||
| ≥ $90,000 | 169 | 24.6 | 19 | 19.0 | 37 | 24.7 | 113 | 25.1 | ||
| Education | ||||||||||
| High school or less | 208 | 27.8 | 29 | 27.6 | 28 | 18.8 | 151 | 30.5 | .080 | |
| Some college or trade school | 236 | 31.6 | 31 | 27.5 | 55 | 36.9 | 150 | 30.4 | ||
| College or post-grad | 304 | 40.6 | 45 | 47.9 | 66 | 44.3 | 193 | 39.1 | ||
| Marital status | ||||||||||
| Married or living together | 579 | 76.3 | 81 | 75.0 | 122 | 81.3 | 376 | 75.0 | .268 | |
| Not married or living together | 180 | 23.7 | 27 | 25.0 | 28 | 18.7 | 125 | 25.0 | ||
| Employment status | ||||||||||
| Retired or unemployed | 450 | 59.8 | 69 | 63.9 | 80 | 54.1 | 301 | 60.7 | .229 | |
| Employed | 302 | 40.2 | 39 | 36.1 | 68 | 45.9 | 195 | 39.3 | ||
| Age at enrollment: mean (SD) | 62.7 (13.4) | 62.7 (12.6) | 59.7 (14.1) | 63.6 (13.2) | .008 | |||||
| 25–49 | 135 | 17.7 | 20 | 18.3 | 36 | 24.0 | 79 | 15.7 | .282 | |
| 50–64 | 279 | 36.7 | 44 | 40.4 | 54 | 36.0 | 181 | 36.1 | ||
| 65–79 | 271 | 35.6 | 34 | 31.2 | 48 | 32.0 | 189 | 37.6 | ||
| ≥80 | 76 | 10.0 | 11 | 10.1 | 12 | 8.0 | 53 | 10.6 | ||
| Clinical Characteristics (CLN) | ||||||||||
| NHL histology | ||||||||||
| Indolent | 361 | 50.2 | 85 | 81.0 | 57 | 40.4 | 219 | 46.3 | <.001 | |
| Aggressive | 358 | 49.8 | 20 | 19.0 | 84 | 59.6 | 254 | 53.7 | ||
| NHL stage at diagnosis | ||||||||||
| Stage I | 210 | 31.3 | 29 | 34.1 | 39 | 28.7 | 142 | 31.6 | .278 | |
| Stage II | 141 | 21.0 | 10 | 11.7 | 31 | 22.8 | 100 | 22.2 | ||
| Stage III | 131 | 19.5 | 23 | 27.1 | 26 | 19.1 | 82 | 18.2 | ||
| Stage IV | 189 | 28.2 | 23 | 27.1 | 40 | 29.4 | 126 | 28.0 | ||
| Sum of treatment types: mean (SD) | 2.1 (1.1) | 2.4 (1.3) | 2.2 (1.1) | 2.1 (1.0) | .006 | |||||
| Surgery | 226 | 30.5 | 25 | 22.9 | 44 | 30.6 | 157 | 32.0 | .235 | |
| Radiation | 364 | 47.8 | 48 | 44.0 | 61 | 40.7 | 255 | 50.8 | .064 | |
| Chemotherapy | 617 | 81.1 | 83 | 76.2 | 120 | 80.0 | 414 | 82.5 | .290 | |
| Bone marrow/stem cell transplant | 119 | 15.6 | 16 | 14.7 | 28 | 18.7 | 75 | 14.9 | .521 | |
| Biologic therapy | 215 | 28.3 | 60 | 55.1 | 59 | 39.3 | 96 | 19.1 | <.001 | |
| Current treatment status | ||||||||||
| Not in treatment | 686 | 90.9 | 38 | 35.5 | 150 | 100.0 | 502 | 100.0 | n/a | |
| Receiving treatment | 69 | 9.1 | 69 | 64.5 | 0 | 0.0 | 0 | 0.0 | ||
| Number of NHL recurrences | ||||||||||
| 0 | 517 | 68.6 | 51 | 47.7 | 120 | 80.5 | 346 | 69.5 | <.001 | |
| ≥1 | 237 | 31.4 | 56 | 52.3 | 29 | 19.5 | 152 | 30.5 | ||
| Age at diagnosis: mean (SD) | 52.3 (14.1) | 54.5 (13.2) | 55.9 (14.2) | 50.7 (14.0) | <.001 | |||||
| Range: | 19–87 | 20–82 | 22–87 | 19–82 | ||||||
| Years since diagnosis: mean (SD) | 10.4 (7.2) | 8.1 (5.1) | 3.8 (0.7) | 12.9 (7.3) | <.001 | |||||
| 2–4 yrs | 182 | 23.9 | 32 | 29.4 | 150 | 100.0 | ||||
| 5–9 yrs | 285 | 37.5 | 48 | 44.0 | 237 | 47.2 | ||||
| 10–14 yrs | 125 | 16.4 | 19 | 17.4 | 106 | 21.1 | ||||
| 15–19 yrs | 81 | 10.6 | 6 | 5.5 | 75 | 15.0 | ||||
| ≥20 yrs | 88 | 11.6 | 4 | 3.7 | 84 | 16.7 | ||||
| General Health (HTH) | ||||||||||
| Secondary cancer | ||||||||||
| Yes | 104 | 13.7 | 16 | 14.8 | 11 | 7.3 | 77 | 15.4 | .040 | |
| No | 655 | 86.3 | 92 | 85.2 | 139 | 92.7 | 424 | 84.6 | ||
| Co-morbidities: mean (SD) | 2.9 (2.1) | 3.0 (2.2) | 2.5 (2.1) | 3.0 (2.1) | .053 | |||||
| Psychosocial (PSO) | ||||||||||
| Social support: mean (SD) | 83.6 (15.9) | 81.7 (16.1) | 85.9 (14.2) | 83.3 (16.3) | .092 | |||||
| Range: | 26–100 | 34–100 | 36–100 | 26–100 | ||||||
| Appraisal of life threat and treatment intensity: mean (SD) | 19.4 (6.0) | 19.0 (6.5) | 19.1 (5.9) | 19.5 (5.8) | .575 | |||||
| Range: | 6–30 | 6–30 | 6–30 | 6–30 | ||||||
| Employment and insurance issues related to cancer: mean (SD) | 1.0 (2.0) | 1.2 (2.2) | 1.0 (2.0) | 1.0 (2.0) | .671 | |||||
| Range: | 0–17 | 0–12 | 0–11 | 0–17 | ||||||
| Post-traumatic Stress (PTS) | ||||||||||
| PTSD symptom clusters: mean (SD) | 0.6 (0.9) | 0.6 (0.9) | 0.6 (0.9) | .014 | ||||||
| Range: | 0–3 | 0–3 | 0–3 | |||||||
| PTSD symptoms: mean (SD) | 26.7 (9.7) | 26.2 (8.3) | 26.0 (9.3) | <.001 | ||||||
| Range: | 17–78 | 17–55 | 17–78 | |||||||
SD: standard deviation; NHL: non-Hodgkin lymphoma; P-value is for the overall comparison
*
Not all variables total 761 due to missing data
†
Active disease represents individuals who self-reported current NHL disease
╪
Short-term survivor group represents individuals 2–4 years post-diagnosis and who reported being disease-free
§
Long-term survivor group represents individuals ≥5 years post-diagnosis and who reported being disease-free